InMed Pharmaceuticals Inc. (NASDAQ: INM) (‘InMed’ or the ‘Company’), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC (‘BayMedica’), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal…
The Government of New Brunswick announced a new comprehensive mineral strategy on Tuesday (March 3), at the 2026 Prospectors…
Adrian Day, president of Adrian Day Asset Management, shares his latest thoughts on what’s moving the gold price, emphasizing…
Rick Rule, proprietor at Rule Investment Media, shares updates on his current strategy in the resource space, mentioning gold,…
Canada’s government unveiled a sweeping new suite of investments this week designed to cement the nation’s role as a…
Alvopetro Energy Ltd. (TSXV: ALV,OTC:ALVOF) (OTCQX: ALVOF) announces February sales volumes of 3,058 boepd (based on field estimates), a…
/Not for distribution to United States newswire services or for dissemination in the United States/ Lithium Africa Corp. (TSXV:…
Lobo Tiggre of IndependentSpeculator.com shares his thoughts on how gold, silver and oil could be impacted by the developing…
